280 related articles for article (PubMed ID: 23226072)
1. New drugs and combinations for the treatment of soft-tissue sarcoma: a review.
Somaiah N; von Mehren M
Cancer Manag Res; 2012; 4():397-411. PubMed ID: 23226072
[TBL] [Abstract][Full Text] [Related]
2. Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.
Nakano K; Takahashi S
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510588
[TBL] [Abstract][Full Text] [Related]
3. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
Sethi TK; Keedy VL
Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
[TBL] [Abstract][Full Text] [Related]
4. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.
Stacchiotti S; Mir O; Le Cesne A; Vincenzi B; Fedenko A; Maki RG; Somaiah N; Patel S; Brahmi M; Blay JY; Boye K; Sundby Hall K; Gelderblom H; Hindi N; Martin-Broto J; Kosela H; Rutkowski P; Italiano A; Duffaud F; Kobayashi E; Casali PG; Provenzano S; Kawai A
Oncologist; 2018 Jan; 23(1):62-70. PubMed ID: 28754721
[TBL] [Abstract][Full Text] [Related]
5. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
6. First-Line Therapy for Metastatic Soft Tissue Sarcoma.
Meyer M; Seetharam M
Curr Treat Options Oncol; 2019 Jan; 20(1):6. PubMed ID: 30675651
[TBL] [Abstract][Full Text] [Related]
7. How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
Van Tine BA; Trent JC
Curr Med Res Opin; 2019 Apr; 35(4):623-629. PubMed ID: 30652922
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
[TBL] [Abstract][Full Text] [Related]
9. Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas.
Recine F; Bongiovanni A; Riva N; Fausti V; De Vita A; Mercatali L; Liverani C; Miserocchi G; Amadori D; Ibrahim T
Onco Targets Ther; 2017; 10():1155-1164. PubMed ID: 28260930
[TBL] [Abstract][Full Text] [Related]
10. A review of soft-tissue sarcomas: translation of biological advances into treatment measures.
Hoang NT; Acevedo LA; Mann MJ; Tolani B
Cancer Manag Res; 2018; 10():1089-1114. PubMed ID: 29785138
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
Nathenson MJ; Conley AP; Sausville E
Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
[TBL] [Abstract][Full Text] [Related]
12. The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma.
Ryan CW; Desai J
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714556
[TBL] [Abstract][Full Text] [Related]
13. Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group.
Tanaka K; Ozaki T
Jpn J Clin Oncol; 2022 May; 52(6):526-530. PubMed ID: 35292817
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin in soft tissue sarcomas.
Petek BJ; Loggers ET; Pollack SM; Jones RL
Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274
[TBL] [Abstract][Full Text] [Related]
15. Molecular targeted therapy for advanced or metastatic soft tissue sarcoma.
Yuan J; Li X; Yu S
Cancer Control; 2021; 28():10732748211038424. PubMed ID: 34844463
[TBL] [Abstract][Full Text] [Related]
16. Salvage Therapy in Advanced Adult Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis of Randomized Trials.
Comandone A; Petrelli F; Boglione A; Barni S
Oncologist; 2017 Dec; 22(12):1518-1527. PubMed ID: 28835514
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Grignani G; D'Ambrosio L; Pignochino Y; Palmerini E; Zucchetti M; Boccone P; Aliberti S; Stacchiotti S; Bertulli R; Piana R; Miano S; Tolomeo F; Chiabotto G; Sangiolo D; Pisacane A; Dei Tos AP; Novara L; Bartolini A; Marchesi E; D'Incalci M; Bardelli A; Picci P; Ferrari S; Aglietta M
Lancet Oncol; 2018 Oct; 19(10):1360-1371. PubMed ID: 30217671
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond).
Carroll C; Patel N; Gunsoy NB; Stirnadel-Farrant HA; Pokras S
Future Oncol; 2022 Oct; 18(32):3651-3665. PubMed ID: 36399116
[TBL] [Abstract][Full Text] [Related]
20. The challenge of finding new therapeutic avenues in soft tissue sarcomas.
Kasper B
Clin Sarcoma Res; 2019; 9():5. PubMed ID: 31007895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]